UNSPSC 51144401: Fipexide

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) TG44VME01D. European Medicines Agency schedules Fipexide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07630MIG. Fipexide generally arises in the molecular formula C20H21CLN2O4.

UNSPSC 51144401 Fipexide is a Commodity code for pharmaceutical products, though recent state and local solicitations tagged with this code actually cover a broader range of health-related procurement: naloxone and drug deactivation systems, generic pharmaceuticals and over-the-counter products, and pharmacy benefit program management services. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration represent the jurisdictional types currently active under this code. The work being solicited ranges from straightforward product procurement—unit-based purchases of specific health commodities with fixed-fee pricing and quarterly delivery schedules—to exploratory market-intelligence gathering ahead of formal pharmacy benefit redesign.

Activity concentrates in Florida, Texas, and Minnesota, with multistate cooperative purchasing vehicles broadening geographic reach across participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through the county's e-Procurement Portal; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capability information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The MMCAP procurement requires manufacturers to supply through three authorized wholesalers and mandates compliance with cGMP and Drug Supply Chain Security Act standards. Set-aside designations and explicit disadvantaged-enterprise restrictions are not identified across these solicitations.